Press
Press Release: PharmaJet partners with Immunomic Therapeutics and EpiVax to develop and deliver COVID-19 Vaccine
Posted on April 15, 2020 by Annie De GrootPress Release: PharmaJet partners with Immunomic Therapeutics and EpiVax to develop and deliver COVID-19 VaccineRead morePress Release: Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19 Using its Investigational UNITE Platform
Posted on April 9, 2020 by Annie De GrootRead the original BusinessWire publication here. ROCKVILLE, MD, PROVIDENCE, RI, and GOLDEN, CO, April 09, 2020 — Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of ...Read morePress Release: EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries
Posted on April 7, 2020 by Annie De GrootPress Release: EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing CountriesRead moreProvidence biotech firm is working on a coronavirus vaccine – Boston Globe interview
Posted on March 30, 2020 by Annie De GrootProvidence biotech firm is working on a coronavirus vaccine - Boston Globe interviewRead morePress Release: EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks
Posted on March 27, 2020 by Annie De GrootPress Release: EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four WeeksRead morePress Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations
Posted on March 24, 2020 by Annie De GrootPress Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populationsRead moreProvidence-based EpiVax developing 2 coronavirus vaccines, needs more funding – WPRI News Channel 12 interview
Posted on March 20, 2020 by Annie De GrootProvidence-based EpiVax developing 2 coronavirus vaccines, needs more funding - WPRI News Channel 12 interviewRead moreProvidence biotech company working to create coronavirus vaccine – Providence NBC 10 News interview
Posted on March 20, 2020 by Annie De GrootProvidence biotech company working to create coronavirus vaccine - Providence NBC 10 News interviewRead morePress Release: Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic
Posted on March 4, 2020 by Annie De GrootMarch 04, 2020 09:00 ET | Source: Generex Biotechnology Corporation MIRAMAR, Fla., March 04, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (https://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a contract with EpiVax (https://epivax.com/) to use their computational tools to predict epitopes that can be used to generate peptide vaccines against the nCOV-2019 corona virus ...Read morePress Release: EpiVax Accelerates COVID-19 Vaccine Development with UGA’s Center for Vaccines and Immunology
Posted on March 4, 2020 by Annie De GrootPROVIDENCE, R.I., Mar. 4, 2020 – EpiVax Inc., a Rhode Island company, announces a collaboration to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine with University of Georgia (UGA, Athens GA) vaccine expert Ted Ross (Director, Center for Vaccines and Immunology (CVI)). The COVID-19 virus emerged in January 2020, impacting over 94,000 individuals, in China and ...Read moreEpiVax devises ‘recipe’ for coronavirus vaccine – Providence Business News interview
Posted on February 21, 2020 by Annie De GrootBy Elizabeth Graham -February 21, 2020 2:35 am Find the full story here. Staying current on the frantic pace of the coronavirus outbreak means following reports by major news outlets for most people, but analysts at EpiVax Inc. are more interested in websites that share genetic sequences of the novel virus. Chinese health officials published the sequence in ...Read moreEpiVax worked for 21 years to be able to make a vaccine in 24 hours!
Posted on February 10, 2020 by Annie De GrootEpiVax worked for 21 years to be able to make a vaccine in 24 hours!Read morePress Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020
Posted on December 27, 2019 by Sarah MonizProvidence, R.I., December 23, 2019 – EpiVax (“EpiVax, Inc.”) continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020. The Business Development team closed 15% more contracts over 2018 and acquired two new clients for ISPRI, the in silico immunogenicity screening and protein re-engineering interface, bringing the ...Read morePress Release: On Eve of New Decade, EpiVax Re-Pledges Commitment to Improving Health Everywhere
Posted on December 20, 2019 by Sarah MonizProvidence, R.I., December 17, 2019 EpiVax, Inc. (“EpiVax”), the home of “fearless science”, announces it will renew their company-wide commitment to “improving human health everywhere” in the new decade (2020). EpiVax has a greater than 20-year tradition of corporate giving to worthy charities, especially those that improve human (or animal) health. Each year a significant portion ...Read morePress release: EpiVax’s Novel Tregitope technology offers promising outcomes in the Treatment of Type 1 Diabetes
Posted on November 6, 2019 by Annie De GrootProvidence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction” in Scientific Reports, 06 Nov 2019, a Nature publication . This research highlights ...Read more
Join our newsletter
We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content. Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.